---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-23-200540"
form_type: "8-K"
ticker: "FBRX"
cik: "0001419041"
company_name: "Forte Biosciences, Inc."
filed_at: "2023-08-01T23:59:59+00:00"
generated_at: "2026-06-12T17:36:15.082985+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Forte Biosciences raises $25M in private placement; announces promising FB-102 data in GvHD

## Summary
- Raised ~$25M gross from private placement with top-tier institutional investors; execs and board purchased $1.16M.
- FB-102 (anti-CD122) showed 90% survival in acute GvHD model vs 0% vehicle, superior to ruxolitinib (60% single agent).
- Combination of FB-102 with ruxolitinib yielded 90% survival vs 30% for ruxolitinib alone in preclinical model.
- Forte plans to advance FB-102 into clinic in 2024; preclinical PoC data supports potential in vitiligo, celiac, alopecia, T1D, and transplant.

## SEC filing metadata
- accession: 0001193125-23-200540
- form_type: 8-K
- ticker: FBRX
- cik: 0001419041
- company_name: Forte Biosciences, Inc.
- filed_at: 2023-08-01T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 1.01, 3.02, 3.03, 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1419041/000119312523200540/0001193125-23-200540-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1419041/000119312523200540/d470879d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-23-200540
- JSON: https://secwatch.observer/filing/0001193125-23-200540.json
- Plain text: https://secwatch.observer/filing/0001193125-23-200540.txt

## Key facts
- Material Agreements
  Forte Biosciences, Inc. entered into Securities Purchase Agreement with certain qualified institutional buyers, institutional accredited investors and certain executive officers, senior management, and members of the Board of Directors of the Company valued at approximately $25 million (effective 2023-07-28).
  - Action: entry
  - Agreement: equity purchase
  - Counterparty: certain qualified institutional buyers, institutional accredited investors and certain executive officers, senior management, and members of the Board of Directors of the Company
  - Value: approximately $25 million
  - Effective: 2023-07-28
  source text: On July 28, 2023, Forte Biosciences, Inc. (the “Company”) entered into a Securities Purchase Agreement (the “Purchase Agreement”) for a private placement (the “Private Placement”) with certain qualified institutional buyers, institutional accredited investors and certain executive officers, senior management, and members of the Board of Directors of the Company (the “Board”) (each, a “Purchaser” and collectively, the “Purchasers”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1419041/000119312523200540/0001193125-23-200540-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.